NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

Similar documents
National Cancer Drugs Fund List - Approved

Top Regimens by Diagnostic Group. April July 2012

Macmillan Publications

Cancer in Ireland with estimates for

ESMO Clinical Practice Guidelines. ECCO GUIDELINES FORUM Brussels, November 27

List of Available TMAs in the PRN

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES

COSD & Source of Referral

What do blood cancer patients want? (And what do we need and expect too?)

Identifying and counting people living with treatable but not curable cancer

Unknown Primary Service for patients at Chesterfield Royal Hospital

Supplementary Online Content

National Cancer Patient Experience Survey 2016 Technical Documentation July 2017

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES

CLIC Sargent Eligibility Criteria

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit

Cancer Waiting Times. 1 April Adjuvant Radical External Beam Radiotherapy Definitions. Version 1.0

Contents. 3 Pneumology Introduction Positron Emission Tomography: Past and Present 1. 2 Fundamentals. xxx

CANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

Overview of 2010 Hong Kong Cancer Statistics

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

Cancer in Ireland : Annual Report of the National Cancer Registry

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

incidence rate x 100,000/year

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

Cancer in Ireland : Annual Report of the National Cancer Registry

Overview of 2009 Hong Kong Cancer Statistics

CODING TUMOUR MORPHOLOGY. Otto Visser

Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers

N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013

Comprehensive Cancer Cover

Cancer in Estonia 2014

Cancer Association of South Africa (CANSA)

Life & Bladder Cancer - The Yorkshire Survey

Information Services Division NHS National Services Scotland

ACR TXIT TM EXAM OUTLINE

How a fully integrated Acute Oncology Service can benefit the busy medical unit

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

Attending Physician Statement- Cancer or Carcinoma in-situ

Outcomes Report: Accountability Measures and Quality Improvements

Information Services Division NHS National Services Scotland

Consultation on publication of new cancer waiting times statistics Summary Feedback Report

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence

Information Services Division NHS National Services Scotland

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

Project Brief. New Cancer Waiting Times. Data Quality Assurance Audit

Palliative care - the opportunities. Dr David Brooks Macmillan Consultant in Palliative Medicine Chesterfield Royal Hospital

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

CHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster

DEPARTMENT OF ONCOLOGY ELECTIVE

The European Commission s science and knowledge service. Joint Research Centre

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Supplementary Online Content

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich

Tumor Comparison. NAACCR Death Clearance Manual Update. Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013

One Palliative Care Annual Report

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996

THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA

Neoplasms/Lymphoma/Leukemia

ALL CANCER (EXCLUDING NMSC)

UK Biobank. Death and Cancer Outcomes Report. September

Title Cancer Drug Phase Status

Dr Hilary Williams. Consultant in Medical Oncology at Velindre Cancer Centre

*

Outcomes Report: Accountability Measures and Quality Improvements

Supplemental Table 1.1: Prostate cancer prognostic tools

Cancer prevalence. Chapter 7

CODING PRIMARY SITE. Nadya Dimitrova

Vacancy list Pathway Boards

SUPPLEMENTARY INFORMATION

Radiation Oncology Study Guide

ALL CANCER (EXCLUDING NMSC)

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

Development status of OPDIVO (nivolumab) 1

West of Scotland Cancer Network. Cancer in Scotland: Monitoring Report April 2008 March 2009

Survival in Teenagers and Young. Adults with Cancer in the UK

Pancreat ic Cancer UK. policy briefing. A cancer of unmet need: the pancreatic cancer research challenge

Meeting : North of Scotland Regional Cancer Advisory Forum Time: pm Date: Wednesday 2 nd July 2014

Overview of Hong Kong Cancer Statistics of 2015

Re-audit of Radiotherapy Waiting Times 2005

Trends in Cancer Survival in NSW 1980 to 1996

21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma,

Clinical indications for positron emission tomography

Cancer of Unknown Primary (CUP) Protocol

Future Direction for Cancer Registries

Introduction. Please note the toolkit aims to share learning and good practice, but it is, of necessity, brief in nature.

Summary of Research and Writing Activities in Oncology

Oncology 101. Cancer Basics

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Location of cancer services and cancer support services in NEMICS region

Transcription:

Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed with MCN lead. MCN newly set up Lead meeting with the MDTs work to start after that. : Green = / Amber = Active Development / Red = Not under development /or stalled

COLORECTAL CANCER MCN: Colorectal MCN Disease: Colorectal Cancer CMG Lead: Mr. M Loudon (Grampian) Active April Colorectal Cancer Last Quarter 2012 Last Quarter 2012 Colorectal Cancer To be initiated GYNAECOLOGICAL CANCER MCN: Gynae Disease: Cervical GYNAE MCN not currently functioning MCN: Gynae Disease: Endometrial : Green = / Amber = Active Development / Red = Not under development /or stalled

GYNAE MCN not currently functioning MCN: Gynae Disease: Ovary GYNAE MCN not currently functioning MCN: Gynae Disease: Vagina - Vulva GYNAE MCN not currently functioning : Green = / Amber = Active Development / Red = Not under development /or stalled

HEAD & NECK MCN: Head and Neck (MSN status?) Disease: Head & Neck Cancer CMG Lead: Dr R. Casasola (Tayside) rcasasola@nhs.net Feb 2013 Active See Oropharyngeal NOSCAN starting document circulated. Highland unable to respond to development due to workload issues (Oropharyngeal CMG NOSCAN DRAFT feb13.ppt) Laryngeal Awaiting feedback from RC before circulation Tongue Oral Cavity Oropharyngeal Yet to be initiated needing info from CMG first Laryngeal Yet to be initiated needing info from CMG first Tongue Yet to be initiated needing info from CMG first Oral Cavity Yet to be initiated needing info from CMG first HPB CANCER MCN: National HPB Disease: Pancreatic Cancer Lindsay Campbell Lindsay Campbell : Green = / Amber = Active Development / Red = Not under development /or stalled

MCN: National HPB Disease: Liver Cancer Lindsay Campbell Lindsay Campbell MCN: National HPB Disease: Biliary Cancer Lindsay Campbell Lindsay Campbell LUNG MCN: LUNG Disease: NSCLC NSCLC Not Started MCN: LUNG Disease: SCLC : Green = / Amber = Active Development / Red = Not under development /or stalled

NSCLC Not Started MCN: LUNG Disease: Mesothelioma NSCLC Not Started Neuro- Neuroendocrine Anaplastic Oligo and Astro National CMG being developed Glioblastoma National CMG being developed Primary Glioma National CMG being developed Anaplastic Oligo and Astro Yet to be initiated needing info from CMG first Glioblastoma Yet to be initiated needing info from CMG first Primary Glioma Yet to be initiated needing info from CMG first : Green = / Amber = Active Development / Red = Not under development /or stalled

SARCOMA Bone Sarcoma Soft Tissue SKIN Malignant Melanoma Squamous Cell Carcinoma : Green = / Amber = Active Development / Red = Not under development /or stalled

UPPER GI MCN: Upper GI MCN Disease: Gastric Cancer CMG Lead: Mr. S. Shimi (Tayside) s.m.shimi@nhs.net Active March 2013 Gastric Cancer CMG circulated update been undertaken within Tayside Regimen List circulated to oncologists Information required from Clinicians in Tayside and Highland MCN: Upper GI MCN Disease: Oesophageal Cancer CMG Lead: Mr. S. Shimi (Tayside) s.m.shimi@nhs.net Active March 2013 Oesopagus CMG circulated update been undertaken within Tayside To be initiated : Green = / Amber = Active Development / Red = Not under development /or stalled

UROLOGY MCN: Disease: Bladder MCN: Disease: Germ Cell Tumour CMG Lead: Graham Macdonald graham.macdonald@nhs.net 01224 552713 Active Germ Cell Tumour Initial document circulated by GM comments received from CM(Tayside) Germ Cell Tumour To be Initiated 4 th April 2013 MCN: Urology Disease: Non-Muscular Invasive Bladder CMG Lead: Thomas Lam Active Feb 2013 thomas.lam@nhs.net 07764587637 2219 Non-musclar invasive bladder Wider Circulation in NOSCAN required : Green = / Amber = Active Development / Red = Not under development /or stalled

MCN: Disease: Penile MCN: Disease: Prostate Castration Resistant MCN: Disease: Androgen Depravation MCN: Urology Disease: Renal CMG Lead: Mr. A. Martindale (Tayside) Active August 2012 : Green = / Amber = Active Development / Red = Not under development /or stalled

Renal Cancer Document close to completion Lead to circulate documentation significant delays, circulation list and consultation e-mail provided in Feb. Not initiated need CMG started first. MCN: Urology Disease: Localised Renal CMG CMG Lead: Prof. S. McClinton (Grampian) Active Feb 2013 Document close to completion CMG Circulated in Grampian awaiting circulation list from renal CMG Not initiated need CMG started first. HAEMATOLOGY Leukaemia AML ALL CML CLL Hairy Cell Myelodysplasia Lymphoma : Green = / Amber = Active Development / Red = Not under development /or stalled

Diffuse Large B Cell Follicular Lymphoma Hodgkin s Lymphoma MCN: Haematology Disease: Mantle Cell Lymphoma CMG Lead: David Meiklejohn Active NOSCAN Mantle CMG shared_270213.ppt Circulated for comments 27/02/2013 Mature T Cell Nodular Lymphocyte Predominant Hodgkin s Lymphoma (NLPHL) Waldenstrom s Macroglobulinaemia? Policy for CNS Prophylaxis in Lymphoma Myeloma MCN: Haematology Disease: Myeloma CMG Lead: Jane Tighe Active Myeloma Copy Circulated : Green = / Amber = Active Development / Red = Not under development /or stalled

Myeloproliferative disorders MCN: Haematology Disease: Essential Thrombocythaemia MCN: Haematology Disease: Polycythaemia Vera BLANK COPIES : Green = / Amber = Active Development / Red = Not under development /or stalled

MCN: Disease: : Green = / Amber = Active Development / Red = Not under development /or stalled